More T-cells were detected in the tumor periphery and tumor core of mice treated with ICIs, and were observed traveling at significantly lower mean velocities (1.75 ± 0.07 μm/min for anti-PD-L1 monotherapy; 2.15 ± 0.08 μm/min for combined anti-CTLA-4 and anti-PD-L1 therapy) than T-cells from the vehicle control cohort (4.60 ± 0.25 μm/min; p < 0.001; Figures 5A–D). The gene discussed is CTLA4; the disease is neoplasm.